recombinant ephb4 hsa fusion protein

Drug Overview

Recombinant EphB4 HSA fusion protein (also known as Vasgene) is a high-precision biological medication designed to combat cancer by disrupting the tumor’s survival network. It is a prime example of a Targeted Therapy and a “Smart Drug.” Unlike traditional chemotherapy that attacks all fast-growing cells, this fusion protein is engineered to find specific markers on cancer cells and blood vessels to stop them from growing and spreading.

This medication is unique because it is a “fusion” of two parts: a specialized protein that targets cancer signaling (EphB4) and a natural human blood protein (Human Serum Albumin or HSA). This corporate-standard design allows the drug to stay in the patient’s body longer and work more effectively. It is currently utilized in advanced clinical research to treat a variety of aggressive solid tumors, offering a new path for patients who have not responded to standard treatments.

• Generic Name: Recombinant EphB4-HSA fusion protein
• US Brand Names: None (Currently an investigational drug)
• Drug Class: EphB4 Receptor Antagonist; Angiogenesis Inhibitor; Fusion Protein
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Currently in Phase II Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

To understand how Recombinant EphB4-HSA works, imagine a cancer cell is a phone that is constantly receiving “calls” telling it to grow and make new blood vessels. The EphB4 receptor is the “antenna” on the cell that receives these calls. This drug acts like a specialized cap that covers the antenna so the signal cannot get through.

At the molecular level, the drug works through a sophisticated multi-step process:

1. Targeting the EphB4-EphrinB2 Pathway: Cancer cells often over-express a receptor called EphB4. Its partner, a protein called EphrinB2, binds to it to trigger growth. The fusion protein specifically binds to EphrinB2, preventing it from touching the EphB4 receptor.
2. Anti-Angiogenesis: Tumors need their own blood supply to survive. By blocking this pathway, the drug stops the signaling that tells the body to grow new, “leaky” tumor blood vessels. This effectively starves the tumor of oxygen and nutrients.
3. Inhibiting Tumor Spread: The EphB4 pathway is also involved in how cancer cells move. By shutting down this signal, the drug makes it harder for cancer cells to break away and travel to other parts of the body (metastasis).
4. HSA Fusion Advantage: By fusing the protein with Human Serum Albumin (HSA), the drug is not filtered out by the kidneys as quickly. This increases its “half-life,” meaning the patient needs fewer treatments and the drug remains at a steady, fighting level in the bloodstream.

FDA-Approved Clinical Indications

As an investigational agent, Recombinant EphB4-HSA is currently available only to patients participating in registered clinical trials.

Oncological Uses (Investigational)

• Kaposi Sarcoma: Particularly in patients with advanced disease.
• Bladder (Urothelial) Cancer: Studied in combination with immunotherapy.
• Head and Neck Cancers: Investigated for recurrent or metastatic cases.
• Solid Tumors: Researching effectiveness in various other cancers like lung and prostate.

Non-Oncological Uses

• There are currently no non-oncological uses for this medication.

Dosage and Administration Protocols

Recombinant EphB4 HSA is administered by a healthcare professional in a hospital or clinic setting via an intravenous drip.

Dose Adjustments:

• Hepatic (Liver) Insufficiency: As albumin is processed by the liver, patients with liver issues are monitored closely; however, specific dose-reduction formulas are still being established in Phase II trials.
• Renal (Kidney) Insufficiency: No major dose adjustments are typically required for mild kidney issues, as the HSA fusion limits renal clearance.

Clinical Efficacy and Research Results

Clinical data from 2020–2025 has focused on using Recombinant EphB4-HSA as a “sensitizer” to make other treatments work better.

• Bladder Cancer Success: In recent Phase II trials, combining this drug with the immunotherapy Pembrolizumab showed an Objective Response Rate (ORR) of approximately 37% in patients who had already failed chemotherapy.
• Kaposi Sarcoma: Research indicates that the drug can lead to significant tumor shrinkage in over 50% of participants in specialized cohorts.
• Survival Rates: Numerical data from 2024 updates suggest a median Progression-Free Survival (PFS) of several months in heavily pre-treated patients, which is a meaningful improvement over standard supportive care.

Safety Profile and Side Effects

Black Box Warning:

None. (As an investigational drug, it has no formal Black Box Warning, but it is strictly monitored for cardiovascular and bleeding risks).

Common Side Effects (>10%)

• Hypertension: Increased blood pressure (common with angiogenesis inhibitors).
• Fatigue: Feeling unusually tired or weak.
• Nausea: General stomach upset.
• Proteinuria: Small amounts of protein found in the urine.

Serious Adverse Events

• Severe Bleeding: Because the drug affects blood vessels, there is a small risk of internal bleeding.
• Thromboembolism: Risk of blood clots in the legs or lungs.
• Infusion Reactions: Fever or chills during the IV drip.

Management Strategies

• Blood Pressure Monitoring: Patients must track their blood pressure daily at home.
• Lab Work: Regular urine tests are performed to monitor for protein, which can indicate kidney stress.

Research Areas

In the fields of Immunotherapy and Regenerative Medicine, Recombinant EphB4 HSA is a major focus. Scientists are investigating how blocking the EphB4 pathway can “unmask” a tumor, making it easier for the body’s natural T-cells to attack it. Current research is exploring the drug’s role in Vascular Regeneration, looking at whether it can help normalize “leaky” blood vessels so that other chemotherapy drugs can reach the center of the tumor more effectively.

Patient Management and Practical Recommendations

Pre-treatment Tests to be Performed

• Baseline Blood Pressure: To ensure it is under control before starting.
• Urinalysis: To check for pre-existing protein in the urine.
• Comprehensive Metabolic Panel (CMP): To check liver and kidney health.

Precautions During Treatment

• Wound Healing: Angiogenesis inhibitors can slow down healing. Notify your surgeon if you have a planned procedure.
• Hydration: Drink plenty of fluids on infusion days.

“Do’s and Don’ts” List

• Do keep a daily log of your blood pressure readings.
• Do report any sudden, severe headaches or changes in vision immediately.
• Don’t start any new over-the-counter medications without asking your oncology team.
• Don’t assume a small amount of swelling in the legs is normal; always report it to your nurse.

Legal Disclaimer

Standard medical information disclaimer: This guide is for informational purposes only and does not constitute medical advice. Recombinant EphB4-HSA fusion protein is an investigational drug and is only available through clinical trials. Always consult with a licensed oncologist or healthcare professional to discuss treatment options, risks, and benefits specific to your medical history. This content reflects clinical data available as of early 2026.